Amylin Pharmaceuticals Reports 2004 Financial Results - 2004
Development Milestones Achieved on Plan - SAN DIEGO, March 2
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN) today reported financial results for the quarter and
year ended December 31, 2004. The Company reported a net loss of
$157.2 million, or $1.67 per share, for the fiscal year ended
December 31, 2004, compared to a net loss of $122.8 million, or
$1.33 per share, for the year ended December 31, 2003. For the
fourth quarter ended December 31, 2004, the Company reported a net
loss of $46.4 million, or $0.49 per share, compared to a net loss
of $17.3 million, or $0.19 per share, for the same period in 2003.
The Company used approximately $163 million of cash for its
operating activities in 2004, and held cash, cash equivalents and
short-term investments of approximately $294 million at December
31, 2004. In February 2005, the Company completed a public offering
of 9.2 million shares of its common stock generating net proceeds
of approximately $191 million. "We achieved all development
milestones for 2004 on plan and within financial expectations,"
said Ginger L. Graham, President and CEO of Amylin Pharmaceuticals,
Inc. "In 2005, we are focused on execution as we prepare for the
potential launch of two first-in-class drug candidates for the
treatment of diabetes, SYMLIN(R) and exenatide." The Company
reported revenues under collaborative agreements of $34.3 million
in fiscal 2004, compared to $85.7 million in fiscal 2003. For the
fourth quarter of 2004, revenues under collaborative agreements
were $6.6 million, compared to $41.0 million in for the same period
in 2003. The fourth quarter of 2003 includes $30 million of
milestone revenue earned pursuant to the Company's exenatide
collaboration agreement with Eli Lilly and Company. Revenue in all
periods consists primarily of the amortization of up-front
payments, expense equalization payments and milestone payments
earned pursuant to the Lilly collaboration agreement. The decrease
in 2004 reflects a shift in the relative proportion of exenatide
development expenses between Amylin and Lilly and a reduction in
milestone revenue. Research and development expenses for 2004
decreased to $119.6 million, compared to $149.4 million in 2003.
For the fourth quarter of 2004, research and development expenses
decreased to $31.3 million, compared to $40.0 million for the same
period in 2003. The decrease in the current periods primarily
reflects reduced expenses for exenatide development following the
completion of the pivotal Phase 3 trials in late 2003, partially
offset by increased costs associated with the advancement of the
Company's other development programs. Selling, general and
administrative expenses for fiscal 2004 increased to $67.0 million,
compared to $56.8 million in fiscal 2003. For the fourth quarter of
2004, selling, general and administrative expenses increased to
$20.2 million compared to $17.9 million for the same period in
2002. The increase in late 2004 reflects increased pre-launch costs
and continued investment in business infrastructure to support
future product launches. Net interest and other income decreased by
$5.9 million for the year ended December 31, 2004. The decrease
reflects the recognition of a one-time gain of $3.6 million in 2003
in connection with an early repayment of debt at a discount and
increased interest expense associated with the Company's $375
million convertible debt placements in July 2003 and April 2004.
Conference Call Amylin will webcast its Quarterly Update Conference
Call today at 12:00 p.m. Eastern/9:00 a.m. Pacific. The Company
will provide supporting details underlying its fourth quarter and
2004 operating results and information regarding key trends and
assumptions for 2005 operations. The call will be webcast live
through Amylin's corporate website and a recording will be made
available following the close of the call. To access the webcast,
please log on to http://www.amylin.com/ approximately fifteen
minutes prior to the call to register, download and install any
necessary audio software. A recording will be available by phone
for 24 hours beginning approximately one hour after the close of
the call and can be accessed at 888-286-8010 (domestic) or
617-801-6888 (international), passcode 26336405. About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. This press release
contains forward-looking statements about Amylin, which involve
risks and uncertainties. The Company's actual results could differ
materially from those discussed herein due to a number of risks and
uncertainties, including that the use of cash from operations in
2005 may be higher than expected, the anticipated payments from
Lilly may not be earned, or FDA requirements for exenatide and/or
SYMLIN approval may not be met or such approvals may be delayed
and/or limited. These and additional risks and uncertainties are
described more fully in the Company's most recently filed SEC
documents, including its recently filed prospectus supplement.
AMYLIN PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands) December 31, 2004 2003 Assets Current assets: Cash
and cash equivalents $60,583 $76,615 Short-term investments 233,173
193,161 Receivables from collaborative partners 5,770 791
Inventories 15,676 11,841 Other current assets 9,156 6,140 Property
and equipment, net 20,739 13,691 Other assets 12,703 8,806 Total
assets $357,800 $311,045 Liabilities and stockholders' equity
(deficit) Accounts payable, accrued expenses and other current
liabilities $37,651 $41,118 Current portion of deferred revenue
4,286 4,286 Other liabilities, net of current portion 7,290 2,196
Deferred revenue, net of current portion 20,943 25,229 Convertible
senior notes 375,000 175,000 Stockholders' equity (deficit)
(87,370) 63,216 Total liabilities and stockholders' equity
(deficit) $357,800 $311,045 CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data) Three Months Ended Years
Ended December 31, December 31, 2004 2003 2004 2003 Revenues under
collaborative agreements $6,597 $41,022 $34,268 $85,652 Operating
Expenses: Research and development 31,335 40,045 119,558 149,431
General and administrative 20,173 17,920 66,958 56,761 Acquired
in-process research and development -- -- -- 3,300 Total operating
expenses 51,508 57,965 186,516 209,492 Operating Loss (44,911)
(16,943) (152,248) (123,840) Interest income (expense), net (1,490)
(395) (4,909) 1,032 Net loss $(46,401) $(17,338) $(157,157)
$(122,808) Net loss per share - basic and diluted $(0.49) $(0.19)
$(1.67) $(1.33) Shares used in computing net loss per share - basic
and diluted 94,377 93,482 94,054 92,396 CONSOLIDATED STATEMENTS OF
CASH FLOWS (in thousands, except per share data) Years Ended
December 31, 2004 2003 Cash used in operating activities $(162,853)
$(143,405) Investing activities: Purchases, sales and maturities of
short-term investments, net (40,679) (115,427) Purchases of
equipment and increase in patents, net (13,115) (12,860) Cash used
in investing activities (53,794) (128,287) Financing activities:
Proceeds from issuance of common stock, net 7,016 172,446 Proceeds
from issuance of convertible debt, net 193,613 169,696 Principal
payments on notes payable and capital leases (14) (63,250) Cash
provided by financing activities 200,615 278,892 Increase
(decrease) in cash and cash equivalents (16,032) 7,200 Cash and
cash equivalents at beginning of year 76,615 69,415 Cash and cash
equivalents at end of year $60,583 $76,615 DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President
Finance and Chief Financial Officer of Amylin Pharmaceuticals,
Inc., +1-858-552-2200 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024